1. Sulfadiazine-trimethoprim combination in the treatment of urinary tract infections
- Author
-
Olli-Veikko Renkonen, Antero Kasanen, and Jouko Tuomisto
- Subjects
Adult ,Male ,medicine.medical_specialty ,Sulfamethoxazole ,Urinary system ,Sulfadiazine ,Pharmacology ,Gastroenterology ,Trimethoprim ,Pharmacokinetics ,Double-Blind Method ,Internal medicine ,Drug Discovery ,medicine ,Humans ,Pharmacology (medical) ,Aged ,Clinical Trials as Topic ,Pyelonephritis ,business.industry ,Incidence (epidemiology) ,General Medicine ,Sulfadiazine - trimethoprim ,Bacterial Infections ,Middle Aged ,Clinical trial ,Drug Combinations ,Infectious Diseases ,Oncology ,Acute Disease ,Urinary Tract Infections ,Drug Evaluation ,Female ,business ,medicine.drug - Abstract
In a clinical double-blind study on 198 patients with a urinary tract infection, no differences were found between comparable groups treated with either sulfadiazine (SD) 1,000 MG/trimethoprim (TM) 320 mg or sulfamethoxazole (SM) 1,600 mg/trimethoprim 320 g daily for 2 weeks. The favorable results were obtained according to the bacteriological control in 85 and 79%, respectively. Also the incidence of side effects was the same (22 and 24%, resp.). The number of cases within which the treatment had to be discontinued did not differ percentually, either (6.6 and 8.4%, resp.). Based on the bacteriological sensitivity tests and the clinical trial, the authors conclude that TM can be combined with SD as well as with SM. Pharmacokinetic advantages, like a lower protein-binding and a lesser metabolism, may even make SD more preferable.
- Published
- 1977